Literature DB >> 26985312

Discovery of Novel Indoline Cholesterol Ester Transfer Protein Inhibitors (CETP) through a Structure-Guided Approach.

Jonathan E Wilson1, Ravi Kurukulasuriya1, Mikhail Reibarkh1, Maud Reiter1, Aaron Zwicker1, Kake Zhao1, Fengqi Zhang1, Rajan Anand1, Vincent J Colandrea1, Anne-Marie Cumiskey2, Alejandro Crespo1, Ruth A Duffy2, Beth Ann Murphy2, Kaushik Mitra2, Douglas G Johns2, Joseph L Duffy1, Petr Vachal1.   

Abstract

Using the collective body of known (CETP) inhibitors as inspiration for design, a structurally novel series of tetrahydroquinoxaline CETP inhibitors were discovered. An exemplar from this series, compound 5, displayed potent in vitro CETP inhibition and was efficacious in a transgenic cynomologus-CETP mouse HDL PD (pharmacodynamic) assay. However, an undesirable metabolic profile and chemical instability hampered further development of the series. A three-dimensional structure of tetrahydroquinoxaline inhibitor 6 was proposed from (1)H NMR structural studies, and this model was then used in silico for the design of a new class of compounds based upon an indoline scaffold. This work resulted in the discovery of compound 7, which displayed potent in vitro CETP inhibition, a favorable PK-PD profile relative to tetrahydroquinoxaline 5, and dose-dependent efficacy in the transgenic cynomologus-CETP mouse HDL PD assay.

Entities:  

Keywords:  CETP inhibition; HDL; cholesterol ester transfer protein; indoline; tetrahydroquinoxaline

Year:  2016        PMID: 26985312      PMCID: PMC4789658          DOI: 10.1021/acsmedchemlett.5b00404

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

Review 1.  Antiinflammatory properties of HDL.

Authors:  Philip J Barter; Stephen Nicholls; Kerry-Anne Rye; G M Anantharamaiah; Mohamad Navab; Alan M Fogelman
Journal:  Circ Res       Date:  2004-10-15       Impact factor: 17.367

2.  Comparison of shape-matching and docking as virtual screening tools.

Authors:  Paul C D Hawkins; A Geoffrey Skillman; Anthony Nicholls
Journal:  J Med Chem       Date:  2007-01-11       Impact factor: 7.446

Review 3.  High-density lipoprotein as a therapeutic target: a systematic review.

Authors:  Inder M Singh; Mehdi H Shishehbor; Benjamin J Ansell
Journal:  JAMA       Date:  2007-08-15       Impact factor: 56.272

Review 4.  High-density lipoprotein and atherosclerosis: the role of antioxidant activity.

Authors:  Salman Bandeali; John Farmer
Journal:  Curr Atheroscler Rep       Date:  2012-04       Impact factor: 5.113

Review 5.  In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport.

Authors:  M N Pieters; D Schouten; T J Van Berkel
Journal:  Biochim Biophys Acta       Date:  1994-01-11

6.  Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.

Authors:  Cameron J Smith; Amjad Ali; Milton L Hammond; Hong Li; Zhijian Lu; Joann Napolitano; Gayle E Taylor; Christopher F Thompson; Matt S Anderson; Ying Chen; Suzanne S Eveland; Qiu Guo; Sheryl A Hyland; Denise P Milot; Carl P Sparrow; Samuel D Wright; Anne-Marie Cumiskey; Melanie Latham; Laurence B Peterson; Ray Rosa; James V Pivnichny; Xinchun Tong; Suoyu S Xu; Peter J Sinclair
Journal:  J Med Chem       Date:  2011-06-17       Impact factor: 7.446

Review 7.  On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.

Authors:  Douglas G Johns; Joseph Duffy; Timothy Fisher; Brian K Hubbard; Michael J Forrest
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 8.  Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport.

Authors:  C Bruce; R A Chouinard; A R Tall
Journal:  Annu Rev Nutr       Date:  1998       Impact factor: 11.848

Review 9.  Future of cholesteryl ester transfer protein inhibitors.

Authors:  Daniel J Rader; Emil M deGoma
Journal:  Annu Rev Med       Date:  2014       Impact factor: 13.739

Review 10.  Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.

Authors:  Nathan B Mantlo; Ana Escribano
Journal:  J Med Chem       Date:  2013-09-12       Impact factor: 7.446

View more
  5 in total

1.  Intramolecular radical cyclization approach to access highly substituted indolines and 2,3-dihydrobenzofurans under visible-light.

Authors:  Clarice A D Caiuby; Akbar Ali; Vinicius T Santana; Francisco W de S Lucas; Marilia S Santos; Arlene G Corrêa; Otaciro R Nascimento; Hao Jiang; Márcio W Paixão
Journal:  RSC Adv       Date:  2018-04-05       Impact factor: 4.036

Review 2.  Literature Survey and Further Studies on the 3-Alkylation of N-Unprotected 3-Monosubstituted Oxindoles. Practical Synthesis of N-Unprotected 3,3-Disubstituted Oxindoles and Subsequent Transformations on the Aromatic Ring.

Authors:  Eszter Kókai; Gyula Simig; Balázs Volk
Journal:  Molecules       Date:  2016-12-26       Impact factor: 4.411

3.  The role of NMR in leveraging dynamics and entropy in drug design.

Authors:  Abhinav Dubey; Koh Takeuchi; Mikhail Reibarkh; Haribabu Arthanari
Journal:  J Biomol NMR       Date:  2020-07-27       Impact factor: 2.835

4.  Anti-selective [3+2] (Hetero)annulation of non-conjugated alkenes via directed nucleopalladation.

Authors:  Hui-Qi Ni; Ilia Kevlishvili; Pranali G Bedekar; Joyann S Barber; Shouliang Yang; Michelle Tran-Dubé; Andrew M Romine; Hou-Xiang Lu; Indrawan J McAlpine; Peng Liu; Keary M Engle
Journal:  Nat Commun       Date:  2020-12-22       Impact factor: 14.919

5.  Controllable access to trifluoromethyl-containing indoles and indolines: palladium-catalyzed regioselective functionalization of unactivated alkenes with trifluoroacetimidoyl chlorides.

Authors:  Hefei Yang; Le-Cheng Wang; Yu Zhang; Dongling Zheng; Zhengkai Chen; Xiao-Feng Wu
Journal:  Chem Sci       Date:  2022-03-03       Impact factor: 9.825

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.